Peptide Characterization and Analytical Testing

Characterization answers two independent questions about a peptide batch: is it the right molecule (identity), and how much of it is the right molecule (purity and content). Identity is established primarily by mass spectrometry, where the measured molecular weight must match the theoretical mass calculated from the sequence. Purity is established by analytical HPLC, where the target peak's area is expressed as a percentage of all detected peaks.

The two measurements are complementary and neither substitutes for the other: a 100% mass match on a 40% pure sample is a documented impurity problem, and a 99% HPLC purity with a wrong mass is a worse one. This pillar explains the techniques behind every field of a trustworthy COA.

Analytical reverse-phase HPLC is the standard purity assay. A small sample is injected on a C18 analytical column and eluted with a water-acetonitrile gradient containing a UV-transparent acid (typically TFA or formic acid). Detection is usually UV at 214 nm, the absorption wavelength of the peptide bond, which responds to nearly all peptide species.

Reported purity depends on the method: a shallow gradient resolves impurities that a steep gradient hides, and detection wavelength changes relative response. When comparing COAs between vendors, compare the methods as well as the numbers. The practical details — column choice, gradients, and what the stationary phase does — are covered in the purification cluster.

Mass spectrometry is the identity backbone of peptide certification. Electrospray ionization (ESI) produces multiply charged ions, giving an m/z envelope from which the neutral molecular weight is deconvoluted; MALDI produces predominantly singly charged ions. A measured mass matching the theoretical mass within instrument tolerance (typically a few ppm on high-resolution instruments) confirms the elemental composition.

Beyond intact mass, MS/MS fragmentation confirms the sequence, which is the strongest identity evidence available. Our cluster covers the technique from the ground up: mass spectrometry for peptide characterization and the beginner-level what is mass spectrometry in peptide testing.

Theoretical peptide mass is calculated by summing the residue masses of the amino acids and adding the mass of one water molecule (18.015 Da) for terminal groups, then adjusting for modifications and counter-ions. The same arithmetic powers every peptide mass calculator: it is deterministic bookkeeping of monoisotopic or average residue masses, not a measurement.

This matters practically because it lets a researcher independently verify a COA: if the certificate's stated molecular weight does not equal the calculated mass of the labeled sequence, something in the documentation is wrong. Related sequence fundamentals — how codons map to peptide sequences and how quaternary structure arises — are covered in the peptide codons and quaternary structure articles.

A complete COA contains: sequence and molecular formula; batch number; appearance; molecular weight (compare against calculation); purity by HPLC with method notes; identity by MS; water content (Karl Fischer); residual solvents (GC); counter-ion; and the analysis date. Two structural checks catch most weak certificates: every analytical claim should name its method, and the batch number on the COA must match the vial.

The full field-by-field walkthrough, including which omissions are red flags, is in this cluster's articles and in the certified peptides guide.

Manufacturer COAs are first-party claims. Third-party testing — where an independent laboratory re-measures identity and purity on a purchased sample — converts claims into evidence. Community-organized third-party test aggregates are a public source of such data for the research peptide market, and learning to read them (sample handling, method transparency, dated results) is a core research skill covered in our vendor independent research pillar.

Analytical numbers are only as good as the method that produced them. The ICH Q2 framework defines the validation parameters that make a result meaningful: specificity (the method separates the target from impurities), accuracy (recovery of known amounts), precision (repeatability), linearity and range (response proportional to concentration), limit of quantitation (the smallest impurity level the method can actually measure), and robustness (tolerance of small method changes).

Translated to COA reading: a purity claim without a method is unverifiable; a method without demonstrated specificity can hide co-eluting impurities; a method with an undisclosed integration rule can inflate area percent. You do not need to run the method to reason about it — only to check that it is stated in enough detail that another analyst could reproduce it.

Peptide-bond absorbance at 214 nm makes nearly all peptide species visible, but not equally: response varies with sequence, and aromatic residues add strong absorbance at 280 nm. This is why the detection wavelength belongs on the COA — purity at 214 nm and purity at 280 nm are different measurements of the same sample, and an impurity rich in aromatics can look larger at 280 than it is.

Area percent has a further subtlety: it reports each peak's fraction of detected UV response, not of mass. A 1% area impurity with double the molar response is closer to 0.5% by mass. None of this makes area percent wrong — it makes it a method-defined quantity, which is exactly why the method notes carry so much information.

LC-MS couples the separation power of HPLC with the identity power of mass spectrometry, and in practice most release testing runs the two together. The HPLC produces the purity chromatogram; the mass spectrometer scans each peak and reports whether its mass matches the target, a deletion, an adduct, or something else. A single LC-MS run can turn an unnamed impurity peak into a named one.

For a researcher auditing a third-party test report, LC-MS is the format to hope for: the total-ion chromatogram plus mass assignments tells you both what was in the vial and how much. The standalone technique background is in our cluster articles on mass spectrometry for peptide characterization and what mass spectrometry is in peptide testing.

Intact mass confirms elemental composition; fragmentation confirms sequence. In MS/MS, the peptide is fragmented along its backbone, producing b- and y-ion series whose masses are read like a barcode of the sequence. A complete ion ladder matching the theoretical fragments is the strongest practical identity evidence a synthetic peptide can carry.

Peptide mapping extends the same logic to larger molecules: enzymatic digestion into characteristic fragments, each confirmed by LC-MS, demonstrating the whole sequence is intact and correctly assembled. Pharmacopeial peptide-mapping chapters formalize this for biotech products. For research peptides, even partial MS/MS coverage distinguishes a genuine matching sequence from a coincidental mass match — isobaric sequences exist, and isotopologues can mislead low-resolution instruments.

Three measurements convert fill mass into net peptide content. Karl Fischer titration quantifies water, typically 2-8% in lyophilized material, and hygroscopic sequences run higher. GC headspace analysis quantifies residual solvents from purification and lyophilization (acetonitrile, TFA traces). Amino acid analysis or quantitative NMR can independently measure total peptide content, and serves as a cross-check on the HPLC-derived figures.

The stack matters because content feeds every downstream calculation. A researcher computing molar concentration from a 5 mg fill that is 8% water, 3% residual solvent, and counter-ion salt is working with roughly 4 mg of peptide — a 20% concentration error if the correction is skipped. The arithmetic lives in our concentration calculation guide; the measurement background lives here.

A purity method is stability-indicating when it can resolve the degradation products of the peptide, not just the synthetic impurities. Demonstrating that requires stress testing: deliberate exposure of samples to heat, acid, base, oxidation, and light, then showing the method separates each resulting degradation product from the intact peak. Regulatory guidance (ICH Q1) formalizes this for drug products; research-grade work borrows the same logic.

Why a researcher cares: degradation pathways (Met oxidation, Asn deamidation, disulfide scrambling, aggregation) are sequence-predictable. A COA purity method that cannot resolve oxidized from intact peptide overstates the useful lifetime of the material. Asking whether a method is stability-indicating is one of the most technical, most answerable questions you can put to a vendor.

A specification is the pass/fail envelope: identity must match (within MS tolerance), purity at or above a stated grade, water below a limit, counter-ion within a range, appearance as described. The COA reports the measurement; the specification defines what the number means. Without a stated specification, "99% purity" is a measurement without a context; with one, it is a released claim that another analyst can check.

Comparing vendors fairly means comparing specifications, not marketing. Two COAs showing 98.5% and 99.2% purity measured by different methods are not rankable to that precision — the honest comparison is method, chromatogram, and consistency across batches, which is precisely the evaluation framework our vendor research pillar applies.

The complete audit sequence: (1) match the batch number on the vial to the COA; (2) recalculate the theoretical mass from the printed sequence and compare with the stated molecular weight; (3) read the purity claim together with its method notes — column, gradient, wavelength; (4) examine the chromatogram for realistic peak shape, integration marks, and impurity distribution; (5) check water and counter-ion entries for the content correction; (6) verify the analysis date plausibility; (7) if third-party data exists, check whether it covers this batch or an older one.

Seven steps, roughly ten minutes, and fully documentable. This is the practical skill the entire characterization cluster exists to teach — and it converts every future purchase decision from trust into verification.

When the standard HPLC/MS stack is not enough, orthogonal assays close the gaps. Ion chromatography quantifies residual TFA and acetate counter-ions directly — the definitive check on a claimed salt conversion. Elemental analysis (CHN) cross-checks composition; ion-coupled plasma methods detect metal contaminants from synthesis or cleavage. Capillary electrophoresis separates charge variants that co-elute in RP-HPLC, catching acidic/basic impurity classes invisible to the standard method.

The buyer-facing point: a COA that includes any orthogonal assay is telling you the lab thought beyond the template — and the specific choice tells you what they were watching for. Counter-ion analysis signals attention to salt form; CE signals attention to charge variants. Documents reveal priorities.

Between HPLC purity and MS identity sits a family of spectroscopic identity checks. UV spectra (from the diode-array detector already in most HPLCs) should match the sequence's aromatic content — a 280 nm band belongs to Trp/Tyr-containing peptides, and its absence in a peptide that should have it is an immediate identity flag. Far-UV circular dichroism reports secondary structure: alpha-helical, beta-sheet, and random-coil signatures are distinguishable, useful for confirming that a structured peptide arrives folded rather than aggregated. Intrinsic fluorescence of Trp residues shifts with environment and can reveal aggregation or misfolding.

These assays are cheap, fast, and often already running inside instruments you own — which makes them the most under-used verification tools in a typical research lab. A DAD spectrum costs nothing extra and would catch a fraction of the mislabeled-vial incidents that mass spec alone misses.

When a peptide has a measurable in-vitro activity — a receptor-binding assay, an enzyme-inhibition readout, a cell-culture response — the bioassay is orthogonal evidence that identity and purity numbers cannot provide: it tests function. A batch with perfect HPLC and MS figures that fails its bioassay is telling you something is wrong that chromatography cannot see — aggregation, wrong salt form in a sensitive system, or a degradation product below detection.

The research-use framing matters here: bioassay verification is standard analytical practice in pharmacology laboratories and says nothing about any human use. For buyers, the practical takeaway is that vendors serving serious research markets increasingly publish functional assay data alongside COAs — and that a vendor whose only functional evidence is testimonials is telling you exactly what tier of operation it runs.

Suppose a COA arrives for a 15-residue peptide. Recalculating the theoretical monoisotopic mass from the printed sequence gives 1,612.8 Da; the COA states 1,758.9 — which is almost exactly the TFA salt mass for three basic residues (3 × 114 = 342... offset by 146, i.e., one acetate plus residual water — consistent with a mixed salt form). Plausible, but the COA does not state the form: a question to send. The purity reads 99.2% at an unstated wavelength with a 10-minute gradient — steep by peptide standards, so impurity shoulders could be compressed: the number is an upper bound, not a measurement of separation. The chromatogram is dated three weeks before your purchase, batch-matched, and shows one 0.8% front shoulder — realistic and honest-looking.

Verdict: mostly credible documentation with two defined gaps (salt-form statement, method steepness). That is what most audits produce — not verdicts, but a short list of specific questions, each checkable, each answered or not by the vendor's reply.

Fair comparison is a method, not a glance at the biggest number. Line up the COAs and compare in a fixed order: the sequence and salt form (identical?), the theoretical mass check (both pass?), the purity methods (comparable gradient and wavelength?), the chromatograms (similar peak counts and shoulders, or is one suspiciously clean?), the content figures (water and counter-ion both stated?), and the analysis dates (both plausible for current stock?). Only after those six rows match does the purity number become a like-for-like comparison — and often the tiebreaker is documentation depth rather than the decimal.

The comparison also exposes the vendor's internal consistency: batch-to-batch variation in purity figures that track a realistic distribution beats identical numbers across months, which as noted elsewhere is statistically implausible. A vendor whose every batch reads exactly 99.2% is reporting a specification, not a measurement.